FDA Reversal Puts Alkermes Depression Drug Back On Track For January Approval
Executive Summary
Reversing an earlier decision, FDA accepted Alkermes' new drug application (NDA) for ALKS 5461 for review, with a target action date of Jan. 31. But the company could still face a tough FDA review.